Search Results

There are 16462 results for: content related to: Examination of Counterfeit Pharmaceutical Labels

  1. Statins and Adverse Cardiovascular Events in Moderate-Risk Females: A Statistical and Legal Analysis with Implications for FDA Preemption Claims

    Journal of Empirical Legal Studies

    Volume 5, Issue 3, September 2008, Pages: 507–550, Theodore Eisenberg and Martin T. Wells

    Article first published online : 5 SEP 2008, DOI: 10.1111/j.1740-1461.2008.00132.x

  2. You have free access to this content
    Counterfeit medicines: a cause for concern in the UK?

    Prescriber

    Volume 18, Issue 14, 19 July 2007, Pages: 16–21, Steve Chaplin

    Article first published online : 19 OCT 2007, DOI: 10.1002/psb.106

  3. Profiting from innovations: the role of new game strategies in the case of Lipitor of the US pharmaceutical industry

    R&D Management

    Volume 40, Issue 2, March 2010, Pages: 124–137, Jina Kang and Allan Afuah

    Article first published online : 8 FEB 2010, DOI: 10.1111/j.1467-9310.2010.00597.x

  4. Industry is more interested in “Me-Too” drugs than in innovation

    Drug Truths: Dispelling the Myths about Pharma R&D

    John L. LaMattina, Pages: 13–22, 2008

    Published Online : 10 NOV 2008, DOI: 10.1002/9780470434673.ch2

  5. Raman Spectroscopy for the Analysis of Counterfeit Tablets

    Infrared and Raman Spectroscopy in Forensic Science

    Kaho Kwok, Lynne S. Taylor, Pages: 561–572, 2012

    Published Online : 10 JAN 2012, DOI: 10.1002/9781119962328.ch9a

  6. Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes

    Rapid Communications in Mass Spectrometry

    Volume 25, Issue 19, 15 October 2011, Pages: 2863–2878, Yuan-Qing Xia, Jim Lau, Timothy Olah and Mohammed Jemal

    Article first published online : 1 SEP 2011, DOI: 10.1002/rcm.5178

  7. Masthead

    Practical Diabetes International

    Volume 16, Issue 7, October 1999, Page: fmi,

    Article first published online : 17 NOV 2005, DOI: 10.1002/pdi.1960160701

  8. RhII-Catalyzed [3+2] Cycloaddition of 2 H-Azirines with N-Sulfonyl-1,2,3-Triazoles

    Chemistry - A European Journal

    Volume 21, Issue 9, February 23, 2015, Pages: 3562–3566, Yun-Zhou Zhao, Hai-Bin Yang, Prof. Dr. Xiang-Ying Tang and Prof. Dr. Min Shi

    Article first published online : 14 JAN 2015, DOI: 10.1002/chem.201406460

  9. Cabinet – Chemical and Biological Informatics Network

    Chemoinformatics in Drug Discovery

    Vera Povolna, Scott Dixon, David Weininger, Pages: 241–269, 2005

    Published Online : 19 MAY 2005, DOI: 10.1002/3527603743.ch10

  10. Clinical Pharmacology in Drug Labeling. The Impact of Drug Metabolism and Clinical Pharmacology on Recommended Dose of Drugs

    Standard Article

    Encyclopedia of Drug Metabolism and Interactions

    Stuart Dombey

    Published Online : 15 MAY 2012, DOI: 10.1002/9780470921920.edm136

  11. Anticounterfeiting Strategies and Their Influence on Attitudes of Different Counterfeit Consumer Types

    Psychology & Marketing

    Volume 32, Issue 8, August 2015, Pages: 842–859, Ram Herstein, Netanel Drori, Ron Berger and Bradley R. Barnes

    Article first published online : 7 JUL 2015, DOI: 10.1002/mar.20822

  12. TRIPS-plus Border Measures and Access to Medicines

    The Journal of World Intellectual Property

    Volume 15, Issue 1, January 2012, Pages: 73–101, Anna Giulia Micara

    Article first published online : 12 DEC 2011, DOI: 10.1111/j.1747-1796.2011.00431.x

  13. Risks and Costs of Counterfeit Pharmaceuticals

    Pharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs

    Mark Davison, Pages: 21–34, 2011

    Published Online : 27 JUN 2011, DOI: 10.1002/9781118023679.ch4

  14. Myopathy after Switching from Brand to Generic Atorvastatin

    Journal of the American Geriatrics Society

    Volume 61, Issue 12, December 2013, Pages: 2254–2255, Omodele Awoniyi and Aidar R. Gosmanov

    Article first published online : 12 DEC 2013, DOI: 10.1111/jgs.12559

  15. Watch out: Themes in timepiece communities of counterfeit consumption

    Journal of Consumer Behaviour

    Volume 12, Issue 4, July/August 2013, Pages: 307–317, Thomas M. Key, Robert E. Boostrom Jr., Mavis T. Adjei and David A. Campbell

    Article first published online : 25 JUN 2013, DOI: 10.1002/cb.1431

  16. Government Issues

    Pharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs

    Mark Davison, Pages: 65–71, 2011

    Published Online : 27 JUN 2011, DOI: 10.1002/9781118023679.ch8

  17. Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand

    Southern Economic Journal

    Volume 79, Issue 1, July 2012, Pages: 97–126, Dhaval Dave and Henry Saffer

    Article first published online : 1 JUL 2012, DOI: 10.4284/0038-4038-79.1.97

  18. Assessing the problem of counterfeit medications in the United Kingdom

    International Journal of Clinical Practice

    Volume 66, Issue 3, March 2012, Pages: 241–250, G. Jackson, S. Patel and S. Khan

    Article first published online : 9 NOV 2011, DOI: 10.1111/j.1742-1241.2011.02826.x

  19. R&D Paradigm Shift and Billion-Dollar Biologics

    Standard Article

    Pharmaceutical Sciences Encyclopedia

    Krishan Maggon

    Published Online : 15 MAR 2010, DOI: 10.1002/9780470571224.pse294

  20. Counterfeit medicines in Poland: opinions of primary healthcare physicians, nurses and lay persons

    Journal of Clinical Nursing

    Volume 22, Issue 3-4, February 2013, Pages: 559–568, Monika Binkowska-Bury, Pawel Januszewicz, Maja Wolan, Marek Sobolewski, Martin Krauze and Zbigniew E Fijalek

    Article first published online : 17 JUL 2012, DOI: 10.1111/j.1365-2702.2012.04166.x